Edgestream Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Edgestream Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-898	Closed	-$311K	–	851
2024 Q1	$311K	Sell	898 -8,134	-90%	-$2.67M	0.02%	719
2023 Q4	$2.92M	Buy	9,032 +3,754	+71%	+$1.18M	0.21%	144
2023 Q3	$1.89M	Buy	+5,278	New	+$2.04M	0.15%	209
2023 Q2	–	Sell	-762	Closed	-$365K	–	723
2023 Q1	$365K	Buy	+762	New	+$357K	0.04%	447
2022 Q4	–	Sell	-8,660	Closed	-$3.61M	–	509
2022 Q3	$3.61M	Buy	8,660 +6,857	+380%	+$3.42M	0.28%	129
2022 Q2	$892K	Buy	+1,803	New	+$939K	0.07%	343
2021 Q3	–	Sell	-499	Closed	-$322K	–	493
2021 Q2	$322K	Sell	499 -7,526	-94%	-$4.58M	0.02%	388
2021 Q1	$4.58M	Buy	+8,025	New	+$4.75M	0.26%	149

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Edgestream Partners's BIO Position: Q2 2024 in Review

Edgestream Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 898 shares — an estimated $311K sold.

Edgestream Partners first reported a position in BIO in Q1 2021 and held it in 8 quarters. The position peaked at $4.58M in Q1 2021. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Edgestream Partners reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Edgestream Partners sold 898 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $311K.
Edgestream Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 8 quarters.
Edgestream Partners's Bio-Rad Laboratories Class A position peaked at $4.58M in Q1 2021.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Edgestream Partners's 13F filing for Q2 2024, filed 9 Aug 2024.